CTi Biopharma Corp (CTIC) Stock
CTIC is no longer traded. CTi Biopharma was acquired by Sobi on June 26, 2023.
Each CTIC share was exchanged for $9.10 in cash. Prices on this page are historical; the last trade was June 22, 2023 at $9.09.
CTi Biopharma stock price history
CTIC final trading statistics
- Final close
- $9.09
- Final trading day
- Jun 22, 2023
- Market cap at delisting
- $1.20B
- Shares outstanding
- 131.88M
- Final 52-week range
- $4.00 – $9.10
- Avg. volume (final 3 mo.)
- 5,924,612
- All-time high (split-adj.)
- $88500.00 · Jun 2003
- All-time low (split-adj.)
- $0.64 · Aug 2019
- Return since IPO
- -100.0%
- Beta
- 0.83
- Book value / share
- -$0.19
- Price / book
- -47.34
CTi Biopharma annual financials
| Fiscal year | Revenue | Net income | EPS |
|---|---|---|---|
| FY2022 | $53.95M | -$91.0M | -$0.85 |
| FY2021 | $0.00 | -$99.6M | -$1.08 |
| FY2020 | $4.2K | -$53.0M | -$0.69 |
| FY2019 | $3.35M | -$42.3M | -$0.69 |
| FY2018 | $26.29M | -$29.3M | -$0.52 |
Last five fiscal years reported before the delisting; fiscal year ending December. EPS is adjusted (non-GAAP) EPS as reported. Source: company filings via EODHD.
About CTi Biopharma Corp
CTI BioPharma Corp., a biopharmaceutical company, focuses on the acquisition, development, and commercialization of novel targeted therapies for blood-related cancers in the United States. It offers VONJO (pacritinib), an an oral kinase inhibitor with specificity for JAK2, FLT3, IRAK1, and CSF1R for the treatment of adult patients with myelofibrosis. CTI BioPharma Corp. has license and collaboration agreement with Teva Pharmaceutical Industries Ltd. and S*BIO Pte Ltd. The company was formerly known as Cell Therapeutics, Inc. and changed its name to CTI BioPharma Corp. in May 2014. CTI BioPharma Corp. was incorporated in 1991 and is headquartered in Seattle, Washington.
CTi Biopharma stock FAQ
What happened to CTi Biopharma stock?
CTi Biopharma was acquired by Sobi on June 26, 2023. Shareholders received $9.10 in cash for each share. CTIC stock stopped trading on the Nasdaq, with a final close of $9.09 on June 22, 2023.
What did CTi Biopharma shareholders receive?
Each CTIC share was converted into $9.10 in cash. The deal was valued at about $1.7 billion.
Is CTIC stock still trading?
No. CTIC was delisted from the Nasdaq on June 26, 2023 and no longer trades on a U.S. exchange.
What was the last price of CTIC stock?
CTIC closed at $9.09 on its final trading day, June 22, 2023, for a market value of about $1.20B.
What were CTi Biopharma's revenue and earnings in its last full fiscal year?
CTi Biopharma reported revenue of $53.95M and net income of -$91.0M in fiscal 2022, its last full year as a public company.
When did CTi Biopharma go public?
CTi Biopharma Corp stock began trading on March 21, 1997.